Drug Profile
PRM 167
Latest Information Update: 19 Feb 2020
Price :
$50
*
At a glance
- Originator Promedior
- Developer Roche
- Class Anti-inflammatories; Antifibrotics; Glycoproteins; Recombinant proteins
- Mechanism of Action Cell differentiation modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Retinal disorders
Most Recent Events
- 13 Feb 2020 Promedior has been acquired and merged into Roche
- 28 Oct 2018 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Intravitreous)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Retinal-disorders in USA (Intravitreous)